(FBT) First Trust NYSE Arca - Ratings and Ratios
Biotechnology, 30, Equal-Weight, Securities
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 18.7% |
| Value at Risk 5%th | 31.1% |
| Relative Tail Risk | 1.04% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.73 |
| Alpha | 8.58 |
| CAGR/Max DD | 0.53 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.345 |
| Beta | 0.790 |
| Beta Downside | 0.766 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.05% |
| Mean DD | 6.44% |
| Median DD | 6.44% |
Description: FBT First Trust NYSE Arca November 16, 2025
The First Trust NYSE Arca Biotechnology Index Fund (NYSE ARCA: FBT) is an ETF that commits at least 90% of its net assets-including any investment borrowings-to the securities that make up its benchmark index. The index is equal-dollar weighted and tracks the performance of 30 leading biotechnology companies, providing a concentrated exposure to the sector.
Key metrics to watch: the fund’s expense ratio is 0.55%, its assets under management (AUM) were approximately $1.2 billion as of the latest quarter, and it has delivered a 12-month total return of roughly 18% (subject to market volatility). Sector drivers include the pace of FDA approvals, which historically correlates with biotech equity performance, and macro-level R&D spending, which has risen about 7% YoY, supporting pipeline growth for the underlying companies.
For a deeper, data-driven analysis of FBT’s risk-adjusted performance and its exposure to upcoming biotech catalysts, you might explore ValueRay’s research tools.
What is the price of FBT shares?
Over the past week, the price has changed by -2.01%, over one month by +2.91%, over three months by +19.55% and over the past year by +22.09%.
Is FBT a buy, sell or hold?
What are the forecasts/targets for the FBT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 218 | 4.4% |
FBT Fundamental Data Overview December 02, 2025
Beta = 0.98
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.35b USD (1.35b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.35b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.35b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.92% (E(1.35b)/V(1.35b) * Re(8.92%) + (debt-free company))
Discount Rate = 8.92% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for FBT ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle